Fengling Min
6 Papers
Fengling Min is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 5 publications.
Chat about Author
Papers
High efficacy of Azacitidine plus HAG in acute myeloid leukemia: an open-label, single-arm, multi-center, phase 2 study
Jun Li,Qi Han,Yan Huang,Yanhui Wei,Jie Zi,Li-Dong Zhao,Zhimei Cai,Xuzhang Lu,Rong Xiao,Yanming Zhang,Xiao Yang,Hao Xu,Naitong Sun,Wanchuan Zhuang,Zhengdong Wu,Yuan chen Xia,Yanli Xu,Bin He,Wei Zhu,Fengling Min,Yongchun Chen,Banghe Ding,Pei Shi,Jing Xie,Hua Tang,Zefa Liu,Bingzong Li,Yu Sun,Hongxia Qiu,Limin Duan,Elanora Dovat,Chunhua Song,Laszlo Szekely,Sinisa Dovat,Zheng Ge +34 more
TL;DR: It is reported that HHT in combination with cytarabine, aclarubicin/daunorubi- cin (HAA/HDA) achieved a higher CR than the standard “ 3 + 7 ” regimen (DA) in treating de novo AML.
BTK inhibitor combined with anti-PD-1 monoclonal antibody for the treatment of CD20-negative primary central nervous system lymphoma: A case report
TL;DR: In this article , a 65-year-old female with CD20-negative diffuse large B-cell lymphoma (DLBCL) whose primary clinical symptom was a persistent headache was treated with a combination of drugs targeting different mechanisms.
Chronic neutrophilic leukemia with JAK2 mutation: is it true chronic neutrophilic leukemia?
Jiapei Gao,Junyin Gao,Fengling Min +2 more
TL;DR: A large number of non-driver gene mutations related to prognosis and therapy have been discovered, and the order in which they are acquired may affect the clinical phenotypes and therapeutic effects of myeloproliferative neoplasms (MPN).
2
[The Efficacy and Safety of Daratumumab-Based Regimen in Treatment of Multiple Myeloma Patients with Renal Impairment].
TL;DR: In this paper , the efficacy and safety of daratumumab in treatment of multiple myeloma (MM) patients with renal impairment (RI) were investigated, and the clinical data of 15 MM patients with RI who received a DARMA-based regimen from January 2021 to March 2022 in three centers were retrospectively analyzed.
High Efficacy of Azacitidine Plus Hag in Acute Myeloid Leukemia: A Multi-Center, Phase 2 Clinical Trial
Jun Ding Li,Qi Han,Yan Huang,Yanhui Wei,Jie Zi,Li-Dong Zhao,Zhimei Cai,Xuzhang Lu,Rong Xiao,Yanming Zhang,Xiao Yang,Hao Xu,Naitong Sun,Wanchuan Zhuang,Zhengdong Wu,Yuan chen Xia,Yanli Xu,Bin He,Wei Zhu,Fengling Min,Yongchun Chen,Banghe Ding,Pei Shi,Jing Xie,Hua Tang,Zefa Liu,Bingzong Li,Yu Sun,Hongxia Qiu,Limin Duan,Chunhua Song,Zheng Ge +31 more
TL;DR: In this paper , the authors evaluated the efficacy and safety of adding Aza to the HAG regimen for acute myeloid leukemia (AML) in a multi-center, single arm, phase 2 clinical trial.